Petros Pharmaceuticals Stock Investor Sentiment

PTPI Stock  USD 0.27  0.02  6.90%   
Under 62% of Petros Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Petros Pharmaceuticals suggests that many traders are alarmed. Petros Pharmaceuticals' investing sentiment shows overall attitude of investors towards Petros Pharmaceuticals.
  

Petros Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Petros Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at www.macroaxis.com         
Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b...
Macroaxis News
over two weeks ago at news.google.com         
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se...
Google News at Macroaxis
over two weeks ago at simplywall.st         
Its Probably Less Likely That Petros Pharmaceuticals, Inc.s CEO Will See A Huge Pay Rise This Year
Simply Wall St News at Macroaxis
over two weeks ago at news.google.com         
Petros Pharmaceuticals stock hits 52-week low at 0.28 By Investing.com - Investing.com Canada
Google News at Macroaxis
over three weeks ago at www.macroaxis.com         
Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b...
Macroaxis News
over a month ago at thelincolnianonline.com         
Petros Pharmaceuticals Trading 30.4 percent Higher Heres Why
news
over a month ago at www.macroaxis.com         
Acquisition by John Shulman of 3382416 shares of Petros Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over a month ago at news.google.com         
Board Reshuffle at Petros Pharmaceuticals Following Resignations - TipRanks
Google News at Macroaxis
over two months ago at thelincolnianonline.com         
Petros Pharmaceuticals, Inc. Short Interest Down 20.5 percent in September
news
over two months ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over two months ago at news.google.com         
Petros Pharmaceuticals sets date for 2024 annual meeting - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway...
Yahoo News
over two months ago at accesswire.com         
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway...
news
over two months ago at finance.yahoo.com         
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Yahoo News
over three months ago at finance.yahoo.com         
Petros Pharmaceuticals Second Quarter 2024 Earnings Beats Expectations
Yahoo News
Far too much social signal, news, headlines, and media speculation about Petros Pharmaceuticals that are available to investors today. That information is available publicly through Petros media outlets and privately through word of mouth or via Petros internal channels. However, regardless of the origin, that massive amount of Petros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Petros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Petros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Petros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Petros Pharmaceuticals alpha.

Petros Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA
09/11/2024
2
Insider Trading
09/20/2024
3
Acquisition by John Shulman of 3382416 shares of Petros Pharmaceuticals subject to Rule 16b-3
10/04/2024
4
Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b-3
11/08/2024
5
Its Probably Less Likely That Petros Pharmaceuticals, Inc.s CEO Will See A Huge Pay Rise This Year
11/13/2024
6
Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3
11/20/2024

Complementary Tools for Petros Stock analysis

When running Petros Pharmaceuticals' price analysis, check to measure Petros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Petros Pharmaceuticals is operating at the current time. Most of Petros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Petros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Petros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Petros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk